Drug intelligence / Profile preview

1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule belonging to the class of N‑phenylureas. It contains a pyrazolo[4,3-d]pyrimidine core linked via an ethylene bridge to a thiazole ring and further substituted with a trifluoromethylaniline urea moiety. The compound is listed in chemical databases as an experimental pharmaceutical but has no approved medical indications or clinical trial activity reported. Its mechanism of action and biological targets are not described in public sources; it may have been investigated as a kinase inhibitor or for other molecular interactions based on its structure but lacks published pharmacological data.[2][4]

Other names
1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea1-(5-(2-((1-methyl-1H-pyrazolo(4,3-d)pyrimidin-7-yl)amino)ethyl)-1,3-thiazol-2-yl)-3-(3-(trifluoromethyl)phenyl)urea3-(5-(2-((1-methyl-1H-pyrazolo(4,3-d)pyrimidin-7-yl)amino)ethyl)-1,3-thiazol‑2‑yl)-1‑(3‑(trifluoromethyl)phenyl)ureaSCHEMBL12725089SCHEMBL-12725089SCHEMBL 12725089
02

Targets

AURKA (Aurora kinase A)NusG (Transcription termination/antitermination protein NusG)

Beyond the preview

Go deeper on 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call